Skip to main content

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.

Publication ,  Journal Article
Vogelzang, NJ; Weissman, LB; Herndon, JE; Antman, KH; Cooper, MR; Corson, JM; Green, MR
Published in: J Clin Oncol
July 1994

PURPOSE: Folic acid antagonists are reported to have activity against mesothelioma. The Cancer and Leukemia Group B (CALGB) undertook this phase II study of the new antifolate, trimetrexate (TMTX), to evaluate its response rate and toxicity in chemotherapy-naive patients with malignant mesothelioma. PATIENTS AND METHODS: Fifty-two patients were accrued to this protocol. Because of concerns about TMTX toxicity in patients with malignant effusions and/or hypoalbuminemia, the first 17 patients were treated at a dose of 6 mg/m2 daily for 5 days every 21 days. Because minimal toxicity was observed, the subsequent 35 patients were treated at a dose of 10 mg/m2. RESULTS: Two of 17 patients (12%) in the 6-mg/m2 treatment group had a partial response (PR) and four of 34 eligible patients (12%) in the 10-mg/m2 treatment group had a PR or regression (R) of assessable disease. No patient achieved a complete response (CR). Median survival durations were 5.0 and 8.9 months in the 6- and 10-mg/m2 treatment groups, respectively, while the 2-year survival rates were identical at 18%. At the 10-mg/m2 dose, toxicity was tolerable, with one toxic death from sepsis and a 12% rate of grade 4 thrombocytopenia and granulocytopenia. CONCLUSION: In this large trial, TMTX showed minor activity in the treatment of malignant mesothelioma. Myelosuppression was mild and dose-related. Future studies of higher doses of TMTX should be considered.

Duke Scholars

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

July 1994

Volume

12

Issue

7

Start / End Page

1436 / 1442

Location

United States

Related Subject Headings

  • Trimetrexate
  • Treatment Outcome
  • Survival Analysis
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mesothelioma
  • Male
  • Humans
  • Female
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vogelzang, N. J., Weissman, L. B., Herndon, J. E., Antman, K. H., Cooper, M. R., Corson, J. M., & Green, M. R. (1994). Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol, 12(7), 1436–1442. https://doi.org/10.1200/JCO.1994.12.7.1436
Vogelzang, N. J., L. B. Weissman, J. E. Herndon, K. H. Antman, M. R. Cooper, J. M. Corson, and M. R. Green. “Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.J Clin Oncol 12, no. 7 (July 1994): 1436–42. https://doi.org/10.1200/JCO.1994.12.7.1436.
Vogelzang NJ, Weissman LB, Herndon JE, Antman KH, Cooper MR, Corson JM, et al. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol. 1994 Jul;12(7):1436–42.
Vogelzang, N. J., et al. “Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.J Clin Oncol, vol. 12, no. 7, July 1994, pp. 1436–42. Pubmed, doi:10.1200/JCO.1994.12.7.1436.
Vogelzang NJ, Weissman LB, Herndon JE, Antman KH, Cooper MR, Corson JM, Green MR. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol. 1994 Jul;12(7):1436–1442.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

July 1994

Volume

12

Issue

7

Start / End Page

1436 / 1442

Location

United States

Related Subject Headings

  • Trimetrexate
  • Treatment Outcome
  • Survival Analysis
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mesothelioma
  • Male
  • Humans
  • Female
  • Aged